"Starved" cells, the company installs a new "safety switch" for cell therapy.

Today, Auxolytic announced that its basic research, conducted in collaboration with researchers at Stanford University, was published in the latest issue of Nature Biotechnologyin the study,, researchers added a new "safety switch" to cell therapy that works by knocking out specific genes in cells, making them dependent on specific nutrientspatients take specific nutrients while receiving cell therapyif serious side effects are observed, nutrients are discontinued, thereby depleting the body's cell therapy and reducing or stopping side effectsin the study, researchers used genome editing to disrupt the expression of urethra monophosphate synthase (UMPS) in polyphostic cells and progenitor human T cellsUMPS is a key protease in the synthesis of ureasides (uridine)urethoside is an indispensable component in the physiological process of RNA synthesis of cellsthe needs of the cells that are knocked out of the UMPS gene depend on externally given urethras to growin the heterotransplant model, the experimental data showed that when the urine side administration stopped, the cells were inactive within a week and could not continue to multiply, after transplanting the edited T cells of the UMPS gene into mice, if the urine side administration is stopped, the cells will not survive and will not cause the graft to resist host disease (GvHD)use nutrients to control the medology (Photo: Auxolytic)) Researchers say in the paper that this method allows for more precise control of cell therapybecause after stopping the administration of urinal sinsides, the cells do not die immediately, but first appear to be stagnant growththis method does not permanently remove cell therapy compared to some "safety switches" that directly kill cells, and by controlling the frequency and dose of administration, cell proliferation can be more finely regulated"Cell therapy has become a breakthrough in the treatment of many diseases, but the potential lying adverse events associated with it limit the number of patients who can benefit," said DrJames Patterson, founder and co-author of the paper at aAuxolytic we believe that the technology we have developed represents a new strategy to improve the safety of cell therapy we look forward to working with companies that promote breakthrough cell therapies to improve their products and expand the number of patients who can benefit from them " References: Foundation Research Published in Nature Biotechnology Showcases Auxolytic's Approach to Developing Nutrient-Based Cell Therapy Controls Retrieved D July 13, 2020, from .2 Wiebking et al., (2020) The briging generates a transgene-free safety switch for cell therapy Nature Biotechnology,